	Under the Pa	aperwork Reduction	n Act of 199	95, no per	sons are rec	uired to respond	to a collecti	on of info	ormation unless it contains a valid OMB con	trol number
A	action Dat	in Chant 2	7.050	4.70	Attorne	y Docket N	umber	2757	6U	
Appıı	cation Dai	ta Sheet 37	CFR	1.76	Applica	ation Numbe	er			
Title of	Invention	FORMULATION	ONS FO	R POOF	RLY SOLI	UBLE DRUG	s	•		
bibliogra This doo	phic data arrang cument may be	jed in a format s	pecified by	y the Uni and subi	ited States nitted to th	Patent and Tra	ademark C	ffice as	ubmitted. The following form contains outlined in 37 CFR 1.76. ing the Electronic Filing System (EFS	
Secre	cy Orde	r 37 CFR	5.2							
☐ Po	ortions or all of	the application	n associ						fall under a Secrecy Order pur not be filed electronically.)	suant to
Appli	cant Info	rmation:								
Applic									Remove	
	ant Authorit	v • Inventor	◯ Le	gal Rep	resentativ	e under 35	J.S.C. 11	7	OParty of Interest under 35 U.S	.C. 118
Prefix				Mi	ddle Na	me		Fam	ily Name	Suffix
	Shlomo							MAG	DASSI	
Resid	ence Inform	ation (Selec	One)	O us	Residenc	y 💽 No	n US Re	sidency	Active US Military Service	9
City	Jerusalem			Count	ry Of Re	esidencei	IL			
Citizer	ıship under	37 CFR 1.41	(b) i	IL			•			
Mailing	g Address o	f Applicant:								
Addre	ss 1	36 Hane	erd Stree	et						
Addre	ss 2									
City	Jerusale	em				Stat	e/Provir	nce		
Postal	Code	96626				Country	IL		•	
Applic	ant 2								Remove	
	ant Authorit	y (Inventor	()Le	gal Rep	resentativ	e under 35	J.S.C. 11	7	Party of Interest under 35 U.S	.C. 118
Prefix				Mi	ddle Na	me		Fam	ily Name	Suffix
	Yoram							SEL/	4	
Resid	ence Inform	ation (Selec	One)	O us	Residenc	y 🕟 No	n US Re	side n cy	Active US Military Service	<u> </u>
City	Raanana	-	Ī	Count	ry Of Re	esidencei	IL			
Citizer	nship under	37 CFR 1.41	(b) i	IL						
Mailing	g Address o	f Applicant:								
Addre	ss 1	Hadas 3	3/16							
Addre	ss 2									
City	Raanan	a				Stat	e/Provir	nce		
Postal	Code	43263				Countryi	IL			
Applic	ant 3					l	1		Remove	
	ant Authorit	nventor	()Le	gal Rep	resentativ	e under 35	J.S.C. 11	7	Party of Interest under 35 U.S	.C. 118
Prefix				Mi	ddle Na	me		Fam	ily Name	Suffix
	Keren							СОН	-	
Resid	ence Inform	ation (Selec	One)	Us	Residenc	y 💿 No	n US Re	side n cy	Active US Military Service	9
City	Jerusalem			Count	ry Of Re	esidencei	IL			

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Date	a Sha	not 37 CED 1 76	Attorr	ney Doo	ket N	u m ber	2 7576l	U				
Application Data	a Sile	eel 37 CFK 1.76	Applic	cation N	lumbe	er						
Title of Invention	FORM	ULATIONS FOR POO	RLY SOI	LUBLE [DRUG	3						
Citizenship under 3	37 CFF	R 1.41(b) i										
Mailing Address of												
Address 1	4	Borochov St.										
Address 2												
City Jerusaler	m				Stat	e/Provir	nce					
Postal Code	6	69922		Cou	ntryi	IL						
All Inventors Must generated within this					ation	blocks	may be)		Add		
Corresponden	ce Ir	nformation:										
Enter either Custor For further informa			the Co	rrespor	ndenc	e Inforn	nation s	sect	ion below	1.		
An Address is	being	provided for the c	orrespo	ndenc	e In fo	rmation	of this	арр	olication.			
Customer Number		20529										
Email Address									Add Emai		Remov	ve Email
Application Inf	orm	ation:										
Title of the Invention	on	FORMULATIONS F	OR POC	ORLY SC	DLUBL	E DRUG	S					
Attorney Docket No	umber	r 27576U			Sı	mall Ent	tity Stat	us (Claimed	×		
Application Type		Nonprovisional			•							
Subject Matter		Utility										
Suggested Class (i	if any)				S	ub Clas	s (if any	/)				
Suggested Techno	logy C	Center (if any)										
Total Number of Dr	rawing	g Sheets (if any)	5		S	uggeste	d Figur	re fo	r Publica	tion (if	f any)	2
Publication In	ıforn	nation:										
Request Early F	Publica	ation (Fee required a	at time o	f Reque	est 37	CFR 1.2	219)					
C. 122(b) and c	ertify iled in	Publish. I her that the invention di another country, or r filing.	sclosed	in the a	ittache	ed applic	ation ha	as n	ot and wi	II not l	be the	subject of
Representative Representative inform this information in the A Enter either Custo are completed the Cus	nation s Applica	should be provided for ation Data Sheet does Number or comp Number will be used for	not const plete the orthe Re	titute a p le Rep presenta	ower o present ative In	of attorney tative N formation	y in the a lame s during p	pplio secti proce	cation (see on below essing.	37 CFF /. If	R 1.32). both	sections
Please Select One:		 Customer Number 	er C) US Pa	atent P	ractitione	er 🗎 🔾) Li	imited Reco	gnition	ı (37 CF	R 11.9)

PTO/SB/14 (11-08)

Approved for use through 09/30/2010. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Da	ta Sheet 37 CFR 1.76	Attorney Docket Number	27576U
Application Da	ita Sileet 37 CFK 1.70	Application Number	
Title of Invention	FORMULATIONS FOR POOR	RLY SOLUBLE DRUGS	
Customer Number	20529		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

Prior Application Status	Expired		Remove				
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)				
10587456 a 371 of international		PCT/IL2005/000093 2005-01-26					
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.							

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

		Re	move					
Application Number	Country i	Parent Filing Date (YYYY-MM-DD)	Priority Claimed					
160095	IL	2004-01-28	● Yes ○ No					
Additional Foreign Priority Data may be generated within this form by selecting the Add button.								

Assignee Information:

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.

of the of it to have an accignment recorded in the office.						
Assignee 1					Remove	
If the Assignee is an O	rgar	nization check here.				
Organization Name	LY	CORED BIO LTD.				
Mailing Address Info	ma	tion:				
Address 1		P.O. BOX 2142				
Address 2						
City		REHOVOT	State/Province			
Country i			Postal Code	76121		
Phone Number			Fax Number			
Email Address				•		
Additional Assignee D button.	ata	may be generated within this fo	rm by selecting the Ad	d	Add	

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.

PTO/SB/14 (11-08) Approved for use through 09/30/2010. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Da	ita Shoot 37 CED 1 76	Attorney Docket Number	27576U
Application Data Sheet 37 CFR 1.76		Application Number	
Title of Invention	FORMULATIONS FOR POOF	RLY SOLUBLE DRUGS	

Signature	/Susanne M. Hopkins/		Date (YYYY-MM-DD)	2010-09-01	
First Name	Susanne M. Last Name		Hopkins	Registration Number	33247

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (6 U.S.C. 552)
 and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
 whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
 individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
 the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.